Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from biotechnology

MorphoSys Stock Skyrockets On Entering Equity Participation and License Agreements With HIBio

MorphoSys AG (NASDAQ:MOR) and Human Immunology Biosciences, Inc. (HIBio), a biotechnology company, have established an equity participation agreement and license agreements to allow HIBio to develop and commercialize MorphoSys’ felzartamab, an anti-CD38 antibody, and MOR210, an anti-C5aR1 antibody. HIBio is a biotechnology company based in South San Francisco that focuses on discovering and…

Benzinga

Donaldson Acquires Early-Stage Biotechnology Company Purilogics

Donaldson Company, Inc. (NYSE:DCI) has acquired Purilogics, LLC, an early-stage biotechnology company, for an initial purchase price of $20 million plus milestone-based earnout payments over the next five years. Founded in 2013 by Jinxiang Zhou and Scott Husson, Purilogics is based in Greenville, South Carolina. Purilogics offers a broad portfolio of purification…

Benzinga

Why This Biotech ETF May Be About to Break Out

There’s a chance shares of the iShares Biotechnology ETF (NASDAQ: IBB) may be about to break out. They are testing a resistance level. If they can get above it, a new uptrend may form.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Bavarian Nordic eyes more monkeypox vaccine orders amid global "wake-up call"

Biotechnology company Bavarian Nordic expects to sign more contracts for its vaccine against monkeypox after "overwhelming" interest from governments around the world, its management told investors on Tuesday.

Reuters

Scotland's biotech sector set to hit key £1 billion milestone

Scotland’s industrial biotechnology community is exceeding growth expectations and is on track to achieve annual turnover of £1.2bn by 2025,…

The National (Scotland)

12 Health Care Stocks Moving In Friday's After-Market Session

Gainers Sana Biotechnology (NASDAQ:SANA) shares moved upwards by 9.1% to $6.1 during Friday's after-market session. The company's market cap stands at $1.1 billion.

Benzinga

Govt.'s progress report reflects resolve to push big development projects

Achievements in public health, pandemic control, IT sector, and biotechnology in focus

The Hindu

Read news from The Economist, FT, and more,
with one subscription

PDS Biotechnology Gains On FDA Fast Track Designation For Lead Candidate

The U.S.

Benzinga

Industrial biotechnology centre reopens innovation fund to new proposals

While any area of biotech will be considered for funding, it is particularly looking for projects focused on agriculture and food

Insider UK

PreMarket Prep: Looking For Biotech Bargains With This Wedbush Analyst

Biotechnology is one sector that peaked ahead of the S&P 500 index. While the S&P 500 index did not peak until January, the SPDR Biotech (NYSE: XBI) peaked in February 2021 and is now 60% lower than its all-time high price ($174.79 vs. $66.50).

Benzinga

One-Trick Pony Boan Biotech Files for Hong Kong IPO Into Tough Market

Key Takeaways: Boan Biotechnology sells only one product so far and is facing stiff competition from other similar drugs Luye Pharma bought Boan in 2020 and is taking it public at a time when markets are bearish By Molly Wen

Benzinga

MGU, Kannur varsity to conduct joint PG courses

In nanoscience, nanotechnology and biotechnology

The Hindu

Entourage Effect In Psychedelics? Preclinical Data Identifies How Formulations Act Synergistically

Panacea Plant Sciences, a Washington State biotechnology company, has discovered formulations that act synergistically with dimethyltryptamine (DMT). The company announced the findings during the Cannabis Science Conference, on May 19.

Benzinga

Norms eased for GM crop research

The guidelines circumvent challenges of using foreign genes to change crops profile

The Hindu

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

AstraZeneca In-Licenses New Suite Of COVID-19 Antibody Candidate(s)

AstraZeneca plc (NASDAQ:AZN) moved to bolster its COVID-19 portfolio of antibodies with a $157 million licensing deal for experimental therapies developed by newly-launched UK-based biotech, RQ Biotechnology Ltd. In addition to the initial sum, AstraZeneca will pay possible royalty payments as part of the exclusive license to develop pre-clinical COVID antibodies engineered by RQ…

Benzinga

HC Wainwright Says This Stock Is Well Capitalized For Value Realization Of Pipeline, Despite COVID-19 Uncertainty

Given the uncertainty, HC Wainwright moderated its COVID-19 franchise estimates, the primary driver of estimate reductions, and price target reduction to $125 (from $200) on Vir Biotechnology Inc (NASDAQ:VIR). The analyst maintained a Buy rating on VIR shares. The analyst continues to view Vir's platform, validated with successful antiviral therapies against Ebola and COVID-19, and pipeline,…

The Street

Cathie Wood Watch: Ark Buys Adaptive Biotech, Smart-Glasses Maker

Ark ETFs bought and sold biotechnology stocks. Ark's flagship fund trails the S&P 500 over the past five years.

Benzinga

Recap: PDS Biotechnology Q1 Earnings

PDS Biotechnology (NASDAQ:PDSB) reported its Q1 earnings results on Wednesday, May 11, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More

Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ: IBB), considered a proxy for the sector, shed close to 3 percent during the week.

ABC News

Biotechnology brains flock to regional Australia, but trials still based in metro areas

Much of Australia's biotech sector is based in regional Australia, but a lack of adequate, but a lack of adequate infrastructure means country patients are still missing out on the early stages of groundbreaking trials.

Benzinga

Where Vir Biotechnology Stands With Analysts

Within the last quarter, Vir Biotechnology (NASDAQ:VIR) has observed the following analyst ratings:

Benzinga

Earnings Outlook For Vir Biotechnology

Vir Biotechnology (NASDAQ:VIR) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Vir Biotechnology will report an earnings per share (EPS) of $3.78.

Benzinga

Why HC Wainwright Is Bullish On This Stock's Hepatitis-B Pipeline

Recently, Vir Biotechnology Inc (NASDAQ:VIR) announced updates on its expansive hepatitis portfolio, including VIR-2218 which is part of a collaboration with Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), and VIR-3434, a monoclonal antibody (mAb). The key highlight of the event was the initial data presented from the Phase 2 MARCH trial of VIR-2218 + VIR-3434 in patients with…

The Independent UK

Former ski resorts owner faces sentencing in Vermont fraud

The former owner of two Vermont ski resorts is facing sentencing for his role in a failed plan to build a biotechnology plant in Vermont using tens of millions of dollars in foreign investors’ money raised through a special visa program that was part of the largest fraud case in…

Dynamite News

Rajesh Gokhale gets addl charge of Director-General CSIR

Secretary of Department of Biotechnology Rajesh S Gokhale on Friday was given additional charge of the post of Director-General, Council of Scientific and Industrial Research (CSIR)-cum-Secretary, Department of Scientific and Industrial Research. Full story on Dynamite News:

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Securities and Exchange Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.